Virologic Suppression on Maraviroc in Treatment-Naïve Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study

Conference Reports for NATAP

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 19th-22nd 2009
Capetown, South Africa


Virologic Suppression on Maraviroc in Treatment-Naïve Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study

	Reported by Jules Levin 5th IAS Capetown July 19-22 2009 Nelson M1, Lazzarin A2, Di Perri G3, Campo R4, Wood R5, Dang N6, Chapman D7, Goodrich J8, Heera J8, Van Der Ryst E9, Mayer H8, Tawadrous M8, Craig C9, Westby M9 1Chelsea and Westminster Hospital, London, UK; 2San Raffaele Scientific Institute, Milan, Italy; 3University of Turin, Turin, Italy; 4University of Miami, Miami, FL, USA; 5University of Cape Town, Cape Town, South Africa; 6Pfizer, Inc., Paris, France; 7Pfizer, Inc., New York, NY, USA; 8Pfizer Global R&D, New London, CT, USA; 9Pfizer Global R&D, Sandwich, UK